The University of British Columbia

Chemokine Therapeutics Corporation

Lakhdar Arab

Ahmed Merzouk

Hassan Salari

Geeta Saxena

Christopher R Tudan

Connie J Eaves

Johanne Cashman

Ian Clark-Lewis

Michael Clark-Lewis, Legal Representative

Mary A Richter, Legal Representative

In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

CXCR4 antagonist treatment of hematopoietic cells

In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

CXC chemokine receptor 4 agonist peptides

Growing community of inventors

Vancouver, Canada

Lakhdar Arab